Patient demographics of included studies
| Author, year | Country of study | sACB | cACB | |||
| Sex (M/F) | Age | Sex (M/F) | Age | Funding source | ||
| Shah34 2015 | India | 7/32 | 66.30 | 13/33 | 68.34 | N/A |
| Li32 2017 | China | 6/24 | 67.70 | 6/24 | 65.90 | China Health Ministry |
| Lee31 2018 | Canada | 41/79 | 65.80 | 24/33 | 65.60 | Department of Anesthesia and Perioperative Care, Vancouver General Hospital |
| Zhang37 2018 | China | 4/21 | 65.00 | 5/18 | 67.00 | National Research Foundation of Nature Sciences |
| Canbek27 2019 | Turkey | 10/50 | 67.10 | 15/48 | 66.90 | N/A |
| Elkassabany28 2019* | USA | 37/16 | 63.90 | 34/18 | 62.20 | N/A |
| Kim29 2019 | South Korea | 2/20 | 66.40 | 3/19 | 70.10 | N/A |
| Lyngeraa33 2019 | Denmark | 13/37 | 69.70 | 21/30 | 70.30 | Ferrosan Medical Devices |
| Turner36 2018 | USA | 21/9 | 68.80 | 13/17 | 70.90 | N/A |
| Lam30 2020 | China | 11/18 | 67.28 | 8/21 | 65.97 | N/A |
| Tak35 2020† | India | 21/37 | 64.10 | 19/38 | 63.30 | N/A |
Only those groups analyzed are included in this table.
*48-hour infusion data presented for cACB.
†Group receiving sACB+iPACK is not presented.
cACB, continuous adductor canal block; N/A, not applicable; sACB, shot adductor canal block.